Parag P Tolat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7784235/publications.pdf

Version: 2024-02-01

19 papers	544 citations	759233 12 h-index	940533 16 g-index
19 all docs	19 docs citations	19 times ranked	852 citing authors

#	Article	IF	CITATIONS
1	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery, 2016, 159, 893-900.	1.9	114
2	Arterial resection at the time of pancreatectomy for cancer. Surgery, 2014, 155, 919-926.	1.9	94
3	Locally advanced pancreas cancer: Staging and goals of therapy. Surgery, 2018, 163, 1053-1062.	1.9	53
4	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery, 2019, 166, 277-285.	1.9	40
5	White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdominal Radiology, 2020, 45, 716-728.	2.1	40
6	Pancreas Transplant Imaging: How I Do It. Radiology, 2015, 275, 14-27.	7.3	38
7	Comparison of Conventional Gadoxetate Disodium–Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion. American Journal of Roentgenology, 2021, 216, 1510-1520.	2.2	28
8	Evolution of the Management of Resectable Pancreatic Cancer. Journal of Oncology Practice, 2016, 12, 772-778.	2.5	24
9	White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals. Abdominal Radiology, 2020, 45, 729-742.	2.1	24
10	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. Journal of Surgical Oncology, 2016, 114, 581-586.	1.7	23
11	Pancreatic adenocarcinoma: cross-sectional imaging techniques. Abdominal Radiology, 2018, 43, 253-263.	2.1	18
12	Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. Journal of Surgical Oncology, 2016, 114, 291-295.	1.7	16
13	Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clinical Genitourinary Cancer, 2017, 15, e897-e901.	1.9	12
14	Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Abdominal Radiology, 2018, 43, 351-363.	2.1	11
15	Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. , 2020, 8, e000584.		4
16	Multimodality Imaging for the Staging of Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 621-637.	1.5	3
17	Skype as a Tool for Resident Education on Call. Journal of the American College of Radiology, 2020, 17, 75-77.	1.8	2
18	Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery Journal of Clinical Oncology, 2017, 35, e15766-e15766.	1.6	0

#	Article	IF	CITATIONS
19	A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study Journal of Clinical Oncology, 2022, 40, TPS220-TPS220.	1.6	0